Receptor desensitization is less of a concern here than intuition might suggest
Tirzepatide may also be prescribed among individuals who are overweight, with a BMI of 27 or higher, if they have other health issues that are associated with their being overweight
Patients should not use semaglutide with other GLP-1 receptor agonists, and safety with other weight-loss medications has not been established
and how we can engage with diverse disciplines, all of which are relevant to analysing these crises and proposing transformative action, despite being already a highly interdisciplinary field
In April 2025, according to an article published by the Heart Rhythm Society, a recent clinical study, TRANSFORM-AF, found that GLP-1 receptor agonists (GLP-1 RAs), typically used for diabetes, may reduce atrial fibrillation (AF)-related events in patients with both obesity and AF
Many people also see reductions in waist circumference and visceral fat, both of which influence cholesterol patterns
